-
Lenvatinib mesylate by Eisai for Metastatic Biliary Tract Cancer: Likelihood of Approval
24 Dec 2023 20:07 GMT
… third-line, monotherapy).
Eisai overview
Eisai is a pharmaceutical company … neurology and oncology. Eisai’s major products include … and peripheral neuropathy. Eisai has production plants in … -proof advantage over your competitors.
Be better informed
GlobalData …
-
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
08 Dec 2023 12:30 GMT
… and development organization. Eisai aspires to discover … of cancers.
About Eisai
Eisai’s Corporate Concept is … Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai … patents attained by competitors; challenges inherent in …
-
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry
28 Nov 2023 16:47 GMT
… vis-à-vis its key competitors in the Biotechnology industry. Through … MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix … Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia …
-
Global Sarcoma Drugs Market Forecast 2023-2032 – Market Size, Drivers, Trends, And Competitors
16 Oct 2023 13:00 GMT
… drugs market include Amgen, Bayer, Eisai, Eli Lilly, GSK, Roche, Johnson … Size And Growth
……
27. Market Competitor Landscape And Company Profiles
28 …
-
Global Hepatocellular Carcinoma Drugs Market Forecast 2023-2032 – Market Size, Drivers, Trends, And Competitors
10 Oct 2023 15:00 GMT
… -Myers Squibb Company, Celgene Corporation, Eisai Co., Ltd., and Eli Lilly … Size And Growth
……
27. Market Competitor Landscape And Company Profiles
28 …
-
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
22 Sep 2023 10:58 GMT
… and development organization. Eisai aspires to discover … of cancers.
About Eisai
Eisai’s Corporate Concept is … Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai … patents attained by competitors; challenges inherent in …
-
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
25 Aug 2023 10:53 GMT
… and development organization. Eisai aspires to discover … of cancers.
About Eisai
Eisai’s Corporate Concept is … Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai … patents attained by competitors; challenges inherent in …
-
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
07 Apr 2023 11:00 GMT
… and development organization. Eisai aspires to discover … of cancers.
About Eisai
Eisai’s Corporate Concept is … Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai … patents attained by competitors; challenges inherent in …
-
Global Vitamin and Minerals Market Forecast 2023-2032 – Market Size, Drivers, Trends, And Competitors
24 Mar 2023 12:33 GMT
… Haus, Pfizer, Daiichi Sankyo, AMWAY, Eisai, Sanofi, GNC, CSPC Pharmaceutical Group … and minerals market major players, competitors' revenues, market positioning, and …
-
Global Lung Cancer Diagnosis and Therapeutics Market [+Competitor Research] | Development Ideas By 2033
16 Jan 2023 13:09 GMT
Global Lung Cancer Diagnosis and Therapeutics Market Top Manufacturers Analysis - AstraZeneca, Eli Lilly, Sanofi, Bayer, Bristol-Myers Squibb, Eisai, AbbVie
NEW YORK CITY, NEW YORK, UNITED STATES, January 16, 2023 /EINPresswire.com/ -- Lung …